








1/24

**Figure 1****Figure 2**




**Figure 3**

3/24

**Figure 4A****Figure 4B****Figure 4C**

**Figure 5**

5/24

**Figure 6A****Figure 6B****Figure 6C**

6/24

Figure 7








Figure 8



7/24



**Figure 9**

8/24

**Figure 10A****Figure 10B**



9/24

**Figure 11****Figure 12**

10/24

Figure 13





Figure 14



11/24

Figure 15





Figure 16



12/24

Figure 17





Figure 18




13/24

**Figure 19**

	10	20	30	40		
<i>Human IL-13</i>	MALLTTVIALTCLGGFAS	P	PVPPSTAL	P	ELIEELVNIT	
<i>Cynomolgus IL-13</i>	MALLTTVIALTCLGGFAS	P	PVPPSTAL	P	ELIEELVNIT	
	MALLTTVIALTCLGGFAS	P	PVPPSTAL		ELIEELVNIT	
	50	60	70	80		
<i>Human IL-13</i>	QNQKAPLCNGSMVWSINLTAG	M	YCAALES	LINVSGCSAIE		
<i>Cynomolgus IL-13</i>	QNQKAPLCNGSMVWSINLTAG	V	YCAALES	LINVSGCSAIE		
	QNQKAPLCNGSMVWSINLTAG		YCAALES	LINVSGCSAIE		
	90	100	110	120		
<i>Human IL-13</i>	KTQRM	L	SGFCPHKVSAGQFSSL	H	VRDTKIEVAQFVKDLL	
<i>Cynomolgus IL-13</i>	KTQRM	L	SGFCPHKVSAGQFSSL	R	VRDTKIEVAQFVKDLL	
	KTQRM		L	SGFCPHKVSAGQFSSL		VRDTKIEVAQFVKDLL
	130					
<i>Human IL-13</i>	HLKKLFREG	R	FN			
<i>Cynomolgus IL-13</i>	HLKKLFREG	Q	FN			
	HLKKLFREG		FN			


**Figure 20**

Effect of a single 10mg/kg dose of BAK502G9 (IgG4) on serum IgE levels in allergic but non-challenged cynomolgus monkeys




14/24

Figure 20B




15/24

**Figure 21**

\*\*  $p < 0.01$  vs s/c control; One-way ANOVA followed by Dunnett's multiple comparisons test

16/24


**Figure 22**

A and B; \* $p < 0.05$ , \*\*  $p < 0.01$  vs huIL-13 control; One-way ANOVA on log-transformed data, followed by Dunnett's multiple comparisons test.




17/24

Figure 23



18/24

**Figure 24**

19/24




Figure 25

20/24





**A.****B.****C.****D.**

Figure 26

21/24




Figure 27




Figure 28

22/24

Figure 29A





Figure 29B




Figure 30

24/24




Figure 31

10 20 30 40 50  
MALLTTVIA LTCLGGFASP GPVPPSTALR ELIEELVNITQNOKAPLCNG  
60 70 80 90 100  
SMVWSINETA GMYCAALESL INVS GCSAIEK TQRM LSGFCP HKVSAGQFS  
110 120 130  
SLHVRDTKIE VAQFVKDLLT HLK LFR EGR FN

Figure 32